Trial of two pills for advanced hormone-positive endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial studies a combination of two oral drugs, elacestrant and everolimus, for advanced or recurrent endometrial cancer that is hormone receptor positive. The goal is to see if this combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and able to take pills by mouth.
- Your endometrial cancer must be hormone receptor positive, meaning it uses hormones to grow.
- You need to have had at least one type of chemotherapy (like carboplatin) in the past.
- If your tumor has a specific marker called dMMR, you must have already tried immunotherapy.
- You must be willing to use effective contraception if you could become pregnant.
- You must have adequate organ function, which will be checked with blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
This trial tests a combination of two targeted pills (sapanisertib and serabelisib) with standard chemo (paclitaxel) for endometrial cancer that has come back or spread. A substudy also looks at combining these drugs with a special diet that lowers insulin levels.
This Phase 1/2 study tests targeted drug(s) for endometrial cancer that has come back or never fully went away after prior treatments. You may be eligible if your tumor can be tested for specific biomarkers and your health allows treatment safely.
This trial tests a new hormone therapy (elacestrant) alone or combined with a targeted pill (abemaciclib) for people with advanced or recurrent endometrial cancer that is hormone-receptor-positive. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This trial tests a combination of two drugs, anlotinib and TQB2450, for people with advanced endometrial cancer that has not responded to previous chemotherapy. The goal is to see if this combination can help control the cancer.
Hear when a new Advanced Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.